<DOC>
	<DOCNO>NCT00748046</DOCNO>
	<brief_summary>The purpose study investigate safety , biodistribution , radiation dosimetry pharmacokinetics three intravenous escalate dose level Xofigo ( Alpharadin ) .</brief_summary>
	<brief_title>Alpharadin™ ( Radium-223 Chloride ) Safety Dosimetry With HRPC That Has Metastasized Skeleton</brief_title>
	<detailed_description>Within U.S. , trial conduct IND sponsor Bayer .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Must ≥18 year age Have histologically cytologically evidence adenocarcinoma prostate Have progressive castrate metastatic disease show least one following : Imaging modality : Radionuclide Bone Scan : New osseous lesion MRI CT : At least 20 % increase sum LD target lesion OR Biochemical progression : A minimum three rise PSA value baseline obtain 1 week apart , 2 measurement 2 week apart Have skeletal metastasis confirm bone scintigraphy within last 4 week . Evidence least 2 bone metastasis bone scan . Have castrate level testosterone ( &lt; 50 ng/ml ) . Treatment maintain castrate level testosterone must continue . Patients fail initial hormonal therapy use either orchiectomy GnRH agonist combination antiandrogen must first progress antiandrogen withdrawal prior eligible . The minimum timeframe document failure antiandrogen withdrawal four week . Have Karnofsky performance status ≥60 % Have life expectancy ≥6 month Have follow laboratory requirement : White Blood Count ( WBC ) ≥3,000/mm3 Absolute Neutrophil Count ( ANC ) ≥1,500/ mm3 Platelet ( PLT ) ≥100,000/ mm3 Hemoglobin ( HGB ) ≥10 mg/dl Bilirubin ≤2.0 mg/dl ( unless patient Gilbert 's syndrome ) AST ALT ≤2,5 time upper institutional limit normal range Serum creatinine ≤2.0 mg/dl Must able willing sign inform consent indicate aware investigational nature study keep policy institution provide write authorization use disclosure protect health information Must willing able comply protocol , agree return hospital followup visit examination Have receive investigational drug within 4 week prior administration Radium223 chloride , schedule receive one treatment posttreatment period Have receive chemo , immunotherapy , external radiotherapy within last 4 week prior administration study drug , recover acute adverse event result therapy Have receive prior hemibody external radiotherapy Have need immediate external radiotherapy Have receive systemic radiotherapy radium223 , strontium89 , samarium153 , rhenium186 rhenium188 treatment bony metastasis within last 24 week prior administration study drug When receive bisphosphonates , change dose within 4 week administration study drug Have start stop systemic steroid within week prior study drug administration , expect subject change systemic steroid medication Have imminent establish spinal cord compression base clinical finding and/or MRI Have currently active ( relapse within last 3 year ) malignancy ( except nonmelanoma skin cancer ) prostate cancer metastasis Have small cell carcinoma Have predominant visceral metastasis ( ≥ 3 lung liver lesion ) symptomatic lymphadenopathy ( scrotal pedal edema ) Any serious illness medical condition , example : uncontrolled infection patient clinical heart failure severe enough cause mark limitation activity , comfortable rest ; patient heart failure severe ( NYHA Heart Failure Class III IV ) Crohn 's disease ulcerative colitis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Biodistribution</keyword>
	<keyword>Radiation dosimetry</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>